Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.4K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
What is the Immune System?01:38

What is the Immune System?

127.1K
Overview
127.1K
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

778
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
778
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.7K
The pathophysiology of pneumonia involves the following steps:
2.7K
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

2.1K
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Studying Early Life Live-Attenuated influenza virus immune Responses (STELLAR): study protocol for an exploratory observational study of the nasal mucosal and systemic immune response in healthy children given an intranasal live-attenuated influenza vaccine.

BMJ open·2026
Same author

Vibrating Mesh and Jet Nebulizer Performance in Pediatric Respiratory Support: A Multi-Modality In Vitro Comparison.

Pharmaceutics·2026
Same author

Lyophilization of biologics: innovations, challenges, and future directions in stabilizing next-generation therapeutics.

Critical reviews in biotechnology·2026
Same author

Dual Core-Shell Loaded Lipid-Polymer Hybrid Nanoparticles as Combination Anti-Infective Delivery Platforms.

Pharmaceutics·2026
Same author

Unravelling the Treatment Strategies for Monkeypox Virus: Success and Bottlenecks.

Reviews in medical virology·2025
Same author

Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model.

Small science·2025

Related Experiment Video

Updated: Jan 22, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.2K

Progress in mucosal immunization for protection against pneumococcal pneumonia.

Viviane Maimoni Gonçalves1, Kan Kaneko2, Carla Solórzano3

  • 1a Laboratory of Vaccine Development, Instituto Butantan , Sao Paulo , Brazil.

Expert Review of Vaccines
|July 16, 2019
PubMed
Summary

New mucosal vaccines could improve protection against pneumococcal pneumonia. Promising delivery systems like nanoparticles offer enhanced immunogenicity and stability, addressing limitations of current vaccines.

Keywords:
Streptococcus pneumoniaebacterial-like particlesexperimental human pneumococcal carriagelive recombinant bacteriananogelsnanoparticlesouter membrane vesiclespneumococcal surface protein Aserotype-independent pneumococcal vaccines

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.6K
Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination
09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

22.6K

Related Experiment Videos

Last Updated: Jan 22, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.2K
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.6K
Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination
09:11

Capsular Serotyping of Streptococcus pneumoniae by Latex Agglutination

Published on: September 25, 2014

22.6K

Area of Science:

  • Immunology
  • Vaccinology
  • Microbiology

Background:

  • Pneumococcus is a leading cause of pneumonia, a major global health threat.
  • Current pneumococcal vaccines show lower efficacy against pneumonia compared to invasive diseases.
  • Serotype replacement is a significant concern with existing vaccines.

Purpose of the Study:

  • To review mucosal immunization strategies for pneumococcal vaccines.
  • To explore delivery systems addressing barriers to mucosal vaccination.
  • To assess potential for serotype-independent protection against pneumonia.

Main Methods:

  • Review of studies on experimental human pneumococcal carriage model.
  • Analysis of various mucosal vaccine delivery approaches (nanoparticles, particles, nanogels).
  • Evaluation of different mucosal administration routes (nasal, pulmonary, sublingual, oral).

Main Results:

  • Nanoparticles, bacterium-like particles, and nanogels show promise as vaccine delivery systems.
  • These systems enhance immunogenicity and offer safety advantages over live-cell approaches.
  • They protect antigens, enable dry formulations, and improve antigen uptake and immune response.

Conclusions:

  • Mucosal vaccination strategies hold potential for improved pneumococcal pneumonia protection.
  • Advanced delivery systems like nanoparticles are key to overcoming mucosal barriers.
  • These approaches may lead to more effective, stable, and broadly protective pneumococcal vaccines.